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Abstract
Background: Gaucher disease is one of the most common lipid-storage disorders, affecting approximately 1
in 75,000 births. Enzyme replacement therapy with recombinant glucocerebrosidase is currently considered
the first-line treatment choice for patients with symptomatic Gaucher disease type 1. Oral substrate reduction
therapy is generally considered a second-line treatment option for adult patients with mild to moderate Gaucher
disease type 1 who are unable or unwilling to receive lifelong intravenous enzyme infusions. The efficacy and safety
of the oral substrate reduction therapy miglustat (Zavesca®) in patients with Gaucher disease type 1 have been
established in both short-term clinical trials and long-term, open-label extension studies. Published data indicate
that miglustat can be used as maintenance therapy in patients with stable Gaucher disease type 1 switched from
previous enzyme replacement therapy.
Case presentation: We report a case of a 44-year-old Caucasian man with Gaucher disease type 1 who was
initially treated with enzyme replacement therapy but, owing to repeated cutaneous allergic reactions, had to be
switched to miglustat after several attempts with enzyme replacement therapy. Despite many attempts,
desensitization treatment did not result in improved toleration of imiglucerase infusions, and the patient became
unwilling to continue with any intravenous enzyme replacement therapy. He subsequently agreed to switch to
oral substrate reduction therapy with miglustat 100 mg twice daily titrated up to 100 mg three times daily over a
short period. Long-term miglustat treatment maintained both hemoglobin and platelet levels within acceptable
ranges over 8 years. The patient’s spleen volume decreased, his plasma chitotriosidase levels stayed at reduced
levels, and his bone mineral density findings have remained stable throughout follow-up. The patient’s quality of
life has remained satisfactory. Miglustat showed good gastrointestinal tolerability in this patient, and no adverse
events have been reported.
Conclusions: Oral miglustat therapy proved to be a valid alternative treatment to intravenous enzyme
replacement therapy for long-term maintenance in this patient with Gaucher disease type 1, who showed
persistent allergic intolerance to imiglucerase infusions. This report exemplifies the type of patient with Gaucher
disease type 1 who can benefit from switching from enzyme replacement therapy to substrate reduction therapy.
Keywords: Gaucher disease, Enzyme replacement therapy, Substrate reduction therapy, Miglustat
* Correspondence: gaegiuffrida@gmail.com
1Regional Reference Center for Rare Diseases, Clinical Division of Hematology
and Transplantation, PO Ferrarotto Hospital, Azienda Ospedaliera-Universitaria
Policlinico-Vittorio Emanuele, Via Citelli, 6-95100, Catania, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Giuffrida et al. Journal of Medical Case Reports  (2016) 10:315 
DOI 10.1186/s13256-016-1060-y
Background
Gaucher disease (GD) is an autosomal recessive inherited
lysosomal storage disease caused by a deficiency of the en-
zyme β-glucocerebrosidase (also called β-glucosidase
[GBA]), which catalyzes the degradation of the sphingo-
lipid glucocerebroside (glucosylceramide) into ceramide
and glucose [1–3]. This deficiency, caused by mutations
on chromosome 1q21 [4], leads to the accumulation of
glucocerebroside in the lysosomes of macrophages that
collect in the liver, spleen, bone marrow, and skeleton [5].
Subsequent progressive visceral involvement has a large
impact on both quality of life and life expectancy.
Traditionally, on the basis of the presence or absence of
neurological symptoms and signs, GD is categorized into
three subtypes [6, 7]. The most common form, Gaucher
disease type 1 (GD1), is generally considered to be non-
neuronopathic in nature and is characterized by hepatos-
plenomegaly, hematological abnormalities (anemia and
thrombocytopenia), and skeletal manifestations such as
osteopenia, fragility fractures, and bone pain. Primarily
neuronopathic forms are less common. GD type 2 is an
acute neuronopathic variant associated with early-onset
and rapidly progressive neurological deterioration as
well as visceral manifestations. GD type 3 is a chronic
neuronopathic form characterized by later onset and
more protracted neurological and visceral involvement.
However, a number of published reports indicate that a
significant proportion of patients with GD1 have neuro-
logical abnormalities [8–10]. The different types of GD
are therefore perhaps better viewed as occurring across
a phenotypic continuum [11, 12]. In light of the weight
of published evidence, it seems appropriate to drop the
terms type 2 and type 3 GD and more representative to
apply the terms acute neuronopathic and chronic neuro-
nopathic GD [13].
Enzyme replacement therapy (ERT) with recombinant
glucocerebrosidase is currently considered the first-line
treatment choice for patients with symptomatic GD1,
providing proven beneficial effects on hematological and
visceral manifestations and improvements in some skel-
etal indices [14, 15]. Oral substrate reduction therapy
(SRT) is generally considered a second-line treatment
option for adult patients with mild to moderate GD1
who are unable or unwilling to receive lifelong intraven-
ous enzyme infusions [16].
The iminosugar miglustat (N-butyldeoxynojirimycin,
Zavesca®; Actelion Pharmaceuticals, Allschwil, Switzerland)
is an inhibitor of glucosylceramide synthase (ceramide-
specific glucosyltransferase), which is the enzyme that
catalyzes the first committed step in the biosynthesis of
glycosphingolipids [17]. The efficacy and safety of
miglustat in patients with GD1 have been established in
both short-term clinical trials and long-term, open-
label extension studies [16, 18, 19]. Further studies have
indicated that miglustat can be used as a maintenance
therapy in patients with stable GD1 switched from pre-
vious ERT [20].
We report a case of a man with GD1 who was initially
treated with ERT but, owing to repeated cutaneous aller-
gic reactions, had to be switched to miglustat after sev-
eral attempts with ERT. The patient’s clinical details are
discussed in relation to the safety profile of miglustat.
Case presentation
A 44-year-old Caucasian man was admitted to our de-
partment in March 2002 with thrombocytopenia and
leukocytosis. The same signs had appeared 2 years be-
fore in another hospital, without a definitive diagnosis.
At admission, he had a platelet count of 123,000/mm3
and a white blood cell count of 8750/mm3. Physical and
neurological examinations did not reveal any physical
symptoms.
The patient’s clinical history revealed a spontaneous
right lung collapse in 1987 (treated by drainage for 1 week)
and an abdominal cardiac valve defect with gastroesopha-
geal reflux since 1989. Liver and spleen hemangioma were
detected by abdominal ultrasound. A bone marrow biopsy
showed 70 % cellularity, with approximately half of the cell
population comprising well-differentiated histiocytes. The
cell cytoplasm was distended and closely packed with fine
granules staining blue with a May-Grünwald-Giemsa
preparation, and centrally located nuclei in some cells
were displaced toward the periphery in others. These fea-
tures were consistent with sea-blue histiocytes.
During follow-up, the patient’s initial hemoglobin
(Hb) concentration and platelet count were 15.4 g/dl
and 154,000/mm3, respectively, and his plasma chito-
triosidase activity was 2150 nmol/h/ml. In May 2002, a
fluorometric assay showed a β-glucosidase activity of
0.30 nmol/h/mg (range 1.7–4.3 nmol/h/mg), which is
compatible with GD. This diagnosis was confirmed by
molecular genetic testing, showing homozygous N370S
mutations. At this point, the patient’s spleen volume
(calculated on the basis of polar diameter) was
12.5 cm3. In addition, bone mineral density (BMD)
measurement by dual-energy X-ray absorptiometry re-
vealed severe osteoporosis (T-score greater than −2.5).
In April 2003, several months after admission, ERT
with imiglucerase (Cerezyme®; Genzyme, Cambridge,
MA, USA) was started with a dosage of 60 IU/kg of
body weight every other week. Approximately 1 year
later (March 2004), the patient underwent upper-right
lobectomy with mediastinal lymphadenectomy for treat-
ment of lung cancer (clear-cell adenocarcinoma). In
follow-up approximately 2.5 years later (December 2005),
a clear improvement in BMD (T-score −1 and less than or
equal to −2.5) (Table 1) and a substantial (> 70 %)
decrease in plasma chitotriosidase to 616 nmol/h/ml were
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observed. The patient’s standard hematological parameters
remained stable (Hb 15.4 g/dl, platelet count 126,000/
mm3). In July 2004, a cutaneous allergic reaction appeared
on the patient’s abdomen and shoulder during the ninth
infusion of imiglucerase, which led to stoppage of the
infusion and subsequent treatment with methylpredniso-
lone 20 mg. Similar adverse reactions occurred at the 10th
and 11th infusions. Thereafter the patient was prepared
30 minutes before starting ERT with intravenous chlor-
pheniramine maleate 5 mg to prevent allergic manifesta-
tions. No further infusion reactions occurred up to the
20th administration, at which point the patient developed
urticarial, pruritus, diarrhea, and chest discomfort.
The patient became unwilling to continue with any
intravenous ERT because of his recurrent allergic mani-
festations, which were poorly prevented by antihistamine
therapy. However, he later agreed to switch to oral therapy
with miglustat (Zavesca®, Actelion Pharmaceuticals),
which was started at a dosage of 100 mg twice daily and ti-
trated up to 100 mg three times daily over a short period
according to the manufacturer’s instructions [21]. He has
since remained on miglustat therapy with good compli-
ance and has not reported any adverse events. His core
hematological parameters and further BMD findings have
remained stable throughout follow-up (Fig. 1a–c). His
spleen volume decreased from 12.0 cm3 at miglustat initi-
ation to 11.1 cm3 in December 2015, after a total of
12 years of ERT and SRT. The patient has never had hepa-
tosplenomegaly, and his liver and renal parameters were
always normal before, during, and after ERT. To date, no
bisphosphonate therapy for osteoporosis has ever been
applied. Last follow-up was in December 2015.
Discussion
GD is one of the most common lipid-storage disorders,
affecting approximately 1 in 75,000 births [22]. The homo-
zygous N370S mutation on the chromosome 1q21 is the
most common genotype observed in affected patients.
Our patient, who was homozygous for N370S, was treated
in accordance with current treatment recommendations
and other literature reports.
Table 1 Dual-energy X-ray absorptiometry findings
Date T-score Treatment
November 2002 Greater than −2.5 ERT
December 2003 −1/-2.5 ERT
July 2005 −1/−2.5 ERT
May 2006 −1/−2.5 ERT
May 2008 −1/−2.5 SRT
March 2011 −1.5 SRT
April 2012 −1.5 SRT
ERT Enzyme replacement therapy, SRT Substrate reduction therapy
Fig. 1 Hematological parameters during initial enzyme replacement
therapy and subsequent miglustat treatment. Black, white, and blue
triangles represent start of enzyme replacement therapy, cessation of
enzyme replacement therapy, and start of miglustat therapy. a)
platelet count during treatment: Black triangle represent start of
enzyme replacement therapy, white triangle represent cessation of
enzyme replacement therapy and Blue triangle represent start of
miglustat therapy. b) hemoglobin concentration during treatment:
black triangle represent start of enzyme replacement therapy, white
triangle represent cessation of enzyme replacement therapy and blue
triangle represent start of miglustat therapy. c) plasma chitotriosidase
activity: Black triangle represent start of enzyme replacement therapy,
white triangle represent cessation of enzyme replacement therapy and
blue triangle represent start of miglustat therapy
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The standard of care for the treatment of the systemic,
nonneuronopathic manifestations of GD is ERT with a re-
combinant analogue of human GBA. Intravenous ERT in-
fusions for GD have been shown to improve hematological
parameters (increased Hb concentrations and platelet
counts), reduce organomegaly, and decrease bone involve-
ment [14, 15]. In most cases, the therapeutic response to
ERT reaches a plateau within the first 2–5 years [14, 15].
The response of our patient to ERT was initially good,
including improvements in Hb and platelets, decreased
bone involvement, and reduced chitotriosidase levels
that were in line with findings reported in the literature
[14, 15]. However, repeated infusion reactions curtailed
the continued use of ERT in this case. The development
of immunoglobulin G antibodies in response to intra-
venous infusions has been reported in approximately
15 % of ERT-treated patients, with many of those
affected experiencing a range of immune reactions, in-
cluding pruritus, flushing, tachycardia, and hypotension
[23–26]. These side effects are usually mild [26, 27],
allowing continuation of therapy after slowing of infu-
sion rates or the use of pharmacological support with
corticosteroids and antihistamines. In patients who re-
spond poorly to these treatments, a desensitization
protocol has successfully been implemented in both
pediatric and adult patients [28, 29]. Unfortunately,
despite many attempts, premedication with methyl-
prednisolone and chlorpheniramine maleate did not
result in improved toleration of imiglucerase infusions
in our patient. ERT was therefore stopped with the
patient’s consent, and it was decided that miglustat
therapy should be commenced.
Miglustat acts as a competitive inhibitor of glucosyl-
ceramide synthase, thereby decreasing the synthesis and
accumulation of glucosylceramide and related glyco-
sphingolipids in reticuloendothelial cell lysosomes [30].
The efficacy of miglustat has previously been demon-
strated over the short term and long term in patients
with GD regarding both reduced visceral involvement
(sustained reductions in both liver and spleen volumes)
and improved hematological parameters [16, 18, 19, 31, 32].
Data also indicate that miglustat is effective as mainten-
ance therapy in patients with stable GD switched from
previous ERT [33–35]. In particular, this agent has
shown beneficial effects on BMD indices in cortical and
trabecular bone, bone marrow burden scores, and bone
pain, which are possibly related to its physicochemical
properties that enable a wide distribution throughout
body tissues [32, 36, 37]. Published data derived from a
long-term safety surveillance program for miglustat
have demonstrated its safety in patients with GD
treated for up to 9 years [38, 39].
Overall, the long-term effects of miglustat in this case
are in agreement with previous findings. Both Hb and
platelet count remained within acceptable ranges through-
out 8 years of follow-up on miglustat since the patient was
switched from previous ERT. His spleen volume de-
creased, and his plasma chitotriosidase levels were main-
tained at reduced levels. The patient’s quality of life has
remained satisfactory.
It is well known on the basis of early clinical trials
in patients with GD that miglustat can lead to gastro-
intestinal disturbances, mainly during the initial weeks
or months of treatment [40]. This is due to reversible
inhibition by orally administered miglustat of intestinal di-
saccharidases, including sucrose and maltase, and to a
lesser extent lactase [40, 41]. As a result of this activity,
the amount of undigested oligosaccharides in the gastro-
intestinal lumen increases, which leads to osmotic diar-
rhea and related symptoms [40]. However, in recent years,
the management of these side effects in miglustat-treated
patients has improved. In particular, simple dietary modi-
fications such as restriction of dietary disaccharide intake,
ideally commenced before initiation of treatment, has
proved useful in reducing gastrointestinal side effects and
in maintaining body-weight gain within normal limits in
pediatric patients [40, 42, 43]. Notably, probiotics rich in
Saccharomyces boulardii, combined with miglustat dose
escalation, have been reported to confer further possible
benefits in this respect [44]. We suggested restriction of
disaccharides for our patient, and we observed accept-
able gastrointestinal tolerability based on the patient’s
self-reports.
Conclusions
We report a case of a patient with GD who underwent
long-term SRT treatment with miglustat. He showed im-
provements in visceral and hematological parameters
during initial ERT, but he had to stop ERT because of an
unacceptable level of adverse infusion reactions. After he
was switched to miglustat, his core disease parameters,
particularly bone indices, remained stable or improved,
and his quality of life was maintained. In terms of toler-
ability, dietary modifications and general patient education
regarding gastrointestinal disturbances that can occur dur-
ing initial miglustat treatment appeared to result in ac-
ceptable compliance with treatment. While reports of
previous open-label trials have indicated that miglustat
can, in general, act as a maintenance therapy in patients
switched from previous intravenous treatment with ERT,
this case provides a specific example of the type of
patient with GD1 in whom switching to oral SRT can
be of particular benefit.
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